# EDGAR Filing Document

**Accession Number:** 0001604191
**File Stem:** 0000000000-25-009623
**Filing Date:** 2025-9
**Character Count:** 3591
**Document Hash:** 78024084d319ecd5b8338fc5992035f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009623.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0000000000-25-009623

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250905

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GridAI Technologies Corp.
- **CENTRAL INDEX KEY:** 0001604191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464993860
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289864

**BUSINESS ADDRESS:**
- **STREET 1:** 433 PLAZA REAL
- **STREET 2:** SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL
- **BUSINESS PHONE:** 561-589-7020

**MAIL ADDRESS:**
- **STREET 1:** 433 PLAZA REAL
- **STREET 2:** SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Entero Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20240516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** First Wave BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20210921

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AzurRx BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20141103
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-083105

## Text-Extract

```

                                                            September 5, 2025

Richard Paolone
Chief Executive Officer
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431

       Re: Entero Therapeutics, Inc.
           Registration Statement on Form S-1
           Filed August 26, 2025
           File No. 333-289864
Dear Richard Paolone:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 filed August 26, 2025
Prospectus Summary
Our Product Candidates, page 8

1.     We note your disclosure on page 8 where you refer to a contemplated
"offering under
       the registration statement on Form S-1 (file number: 333-287185)."
Please revise your
       disclosure to clarify the registration statement you reference has not
been declared
       effective and you have not raised any proceeds from the offering.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
 September 5, 2025
Page 2

time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jason Drory at 202-551-8342 or Laura Crotty at
202-551-7614 with
any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Ross David Carmel, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._